Yukimasa Hatachi
Overview
Explore the profile of Yukimasa Hatachi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katakami N, Nagata K, Nakakura A, Okamoto T, Kaneda T, Oki M, et al.
Jpn J Clin Oncol
. 2024 Sep;
55(1):67-74.
PMID: 39311098
Background: There is an increased risk of acute exacerbation of idiopathic interstitial pneumonia when treating patients with advanced non-small cell lung cancer with idiopathic interstitial pneumonia. There is no standard...
2.
Katakami N, Nishimura T, Hidaka Y, Hata A, Nishino K, Mori M, et al.
Lung Cancer
. 2023 Jun;
182:107261.
PMID: 37307753
Background: Zoledronic acid (ZA) reduces the incidence of skeletal-related events (SREs) in patients with bone metastases from solid tumors. However, the optimal dosing interval of ZA for patients with lung...
3.
Harada T, Togawa T, Miyamoto H, Matsushita Y, Hatachi Y
Clin Case Rep
. 2023 Apr;
11(4):e7218.
PMID: 37077723
High-grade myofibroblastic sarcoma is a rare mesenchymal tumor with a high recurrence and metastatic rate. Few cases of high-grade myofibroblastic sarcomas have been reported. Herein, we report a rare case...
4.
Moriwaki T, Nishina T, Sakai Y, Yamamoto Y, Shimada M, Ishida H, et al.
Jpn J Clin Oncol
. 2022 Apr;
52(7):725-734.
PMID: 35470391
Objective: Many clinical trials for older patients with metastatic colorectal cancer have been conducted, and fluoropyrimidine and bevacizumab are standard treatments. However, the relationship between age and the efficacy and...
5.
Hatachi Y, Mohan S, Kotake T, Satake H, Okita Y, Yasui H, et al.
Cancer Diagn Progn
. 2022 Apr;
2(1):101-106.
PMID: 35400007
Background/aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy...
6.
Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, et al.
Front Oncol
. 2021 Jul;
11:688709.
PMID: 34211856
Background: Primary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC). Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been introduced...
7.
Niisato Y, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, et al.
Anticancer Res
. 2021 Apr;
41(4):2203-2207.
PMID: 33813435
Background/aim: In later-line treatment of metastatic colorectal cancer (mCRC), trifluridine/tipiracil is often selected because regorafenib is difficult to use in patients with comorbidities such as thrombosis, hemorrhage, or cardiac events....
8.
Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, et al.
Front Oncol
. 2021 Mar;
11:576036.
PMID: 33763345
The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and...
9.
Ogata M, Kotaka M, Ogata T, Hatachi Y, Yasui H, Kato T, et al.
PLoS One
. 2020 Jun;
15(6):e0234314.
PMID: 32530932
Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic colorectal cancer patients previously treated with standard chemotherapies; therefore, we compared the efficacy and safety of these two treatments. Patients...
10.
Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, et al.
Int J Clin Oncol
. 2019 Dec;
25(4):614-621.
PMID: 31838590
Background: Although regorafenib or trifluridine/tipiracil (FTD/TPI) has been recognized as a later-line standard treatment in patients with metastatic colorectal cancer (mCRC), not all patients have beneficial outcomes. This study aimed...